Hepatitis B virus infection in hemodialysis populations: progress toward prevention.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 20075953.
- Also identified by DOI 10.1038/ki.2009.456.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Hemodialysis patients are at increased risk of acquiring hepatitis B virus (HBV) infection. Administration of the standard HBV vaccine is suboptimal as a means of prevention because of an impaired seroconversion response in individuals with chronic kidney disease. Surquin and colleagues describe a novel vaccine adjuvant system that increases speed of seroconversion and duration of seroprotection compared with older vaccine formulations. However, its ability to improve overall seroconversion response remains unproven.
Medical subject headings
- Hepatitis B
- Hepatitis B Vaccines
- Kidney Failure, Chronic